Rifaximin-a reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial
Vishal C. Patel et al.
- Rifaximin reduced gut-derived systemic inflammation by suppressing oralisation of the gut microbiome.
- Rifaximin suppressed mucin-degrading species rich in sialidase, e.g. Streptococcus and Veillonella spp.
- Rifaximin promotes an intestinal environment augmenting re- sponses to pathobionts and promoting gut barrier repair.
- Patients treated with rifaximin were less likely to develop infections
In this clinical trial, we examined the underlying mechanism of ac- tion of an antibiotic called rifax- imin-a which has been shown to be an effective treatment for a complication of chronic liver dis- ease which effects the brain (termed encephalopathy). We show that rifaximin-a suppresses gut bacteria that translocate from the mouth to the intestine and cause the intestinal wall to become leaky by breaking down the protective mucus barrier. This suppression resolves encephalopathy and re- duces inflammation in the blood, preventing the development of infection.
Background & Aims: Rifaximin-a is efficacious for the prevention of recurrent hepatic encephalopathy (HE), but its mechanism of action remains unclear. We postulated that rifaximin-a reduces gut microbiota-derived endotoxemia and systemic inflammation, a known driver of HE.
Methods: In a placebo-controlled, double-blind, mechanistic study, 38 patients with cirrhosis and HE were randomised 1:1 to receive either rifaximin-a (550 mg BID) or placebo for 90 days. Primary outcome: 50% reduction in neutrophil oxidative burst (OB) at 30 days. Secondary outcomes: changes in psychometric hepatic encephalopathy score (PHES) and neurocognitive func- tioning, shotgun metagenomic sequencing of saliva and faeces, plasma and faecal metabolic profiling, whole blood bacterial DNA quantification, neutrophil toll-like receptor (TLR)-2/4/9 expression and plasma/faecal cytokine analysis.
Results: Patients were well-matched: median MELD (11 rifax- imin-a vs. 10 placebo). Rifaximin-a did not lead to a 50% reduc- tion in spontaneous neutrophil OB at 30 days compared to baseline (p = 0.48). However, HE grade normalised (p = 0.014) and PHES improved (p = 0.009) after 30 days on rifaximin-a. Rifaximin-a reduced circulating neutrophil TLR-4 expression on day 30 (p = 0.021) and plasma tumour necrosis factor-a (TNF-a) (p <0.001). Rifaximin-a suppressed oralisation of the gut,
reducing levels of mucin-degrading sialidase-rich species, Streptococcus spp, Veillonella atypica and parvula, Akkermansia and Hungatella. Rifaximin-a promoted a TNF-a- and interleukin- 17E-enriched intestinal microenvironment, augmenting anti-bacterial responses to invading pathobionts and promoting gut barrier repair. Those on rifaximin-a were less likely to develop infection (odds ratio 0.21; 95% CI 0.05-0.96).
Conclusion: Rifaximin-a led to resolution of overt and covert HE, reduced the likelihood of infection, reduced oralisation of the gut and attenuated systemic inflammation. Rifaximin-a plays a role in gut barrier repair, which could be the mechanism by which it ameliorates bacterial translocation and systemic endotoxemia in cirrhosis.
Clinical Trial Number: ClinicalTrials.gov NCT02019784.
LEGGI TUTTO https://doi.org/10.1016/j.jhep.2021.09.010